Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field TICAGRELOR
Haematology · Haematology · Level 2
 TIROFIBAN
Haematology · Haematology · Level 3
Mechanism of action

Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking

Antagonises the GpIIb/IIIa
receptor, preventing the
binding of fibrinogen and
platelet crosslinking and
aggregation.
Absorption

BA=40%

 —
Metabolism

Metabolized by CYP3A4

Limited metabolism in humans.
Excretion —

Excreted in urine and faeces, mostly
unchanged
Half-life —

HL 1.9-2.2 hrs
Adverse Effects Toxicity —

Haemorrhage
Difficulty reversing agent
Dose adjustment in renal impairment
Class Group

Antiplatelet

Antiplatelet
Introduction

ADP Receptor Antagonist - Thienopyridine

GP IIb/IIIA Inhibitor
Legacy Cicm Level

Level 3

Level 3
Main Action

Platelet inhibition

Platelet inhibition